PARELETO trial of parenteral retinol palmitate in very preterm infants

Phase 2, open-label, single-arm trial of retinyl palmitate in bronchopulmonary dysplasia (BPD), sponsored by Aspire Pharma. Primary endpoints: Relative increase in serum retinol levels at Day 28 compared to baseline, Incidence of treatment-emergent adverse events and adverse events of special interest and 1 more. Planned start Oct 2025; status: authorised.